Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental ...
These biomarker changes occurred alongside clinical stabilization or improvement, with no serious treatment-related adverse events.
Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding ...
Tiziana Life Sciences is following biotech’s third-quarter cull trend, though it’s attempting to do so more covertly, putting several of its pipeline programs on the shelf in a “near-term focus” ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results